Drug-induced changes in the T-wave morphology

Drug Safety

Volumn 32, Issue 7, 2009, Pages 613-617

  Malik, Marek ^a,b,c  

^a St Paul's Cardiac Electrophysiology   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c SPCE London   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLONE; SOTALOL;

HEART ARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HUMAN; NOTE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; T WAVE; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; CARDIAC ELECTROPHYSIOLOGY; DRUG DESIGN; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; TORSADES DE POINTES;

EID: 67649268399     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-200932070-00007     Document Type: Note

References (17)

1. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacokinetics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231-8
2. Honig PK, Wortham DC, Zamani K, et al. Terfenadineketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8
3. Monlun E, Pillet O, Cochard JF, et al. Prolonged QT interval with halofantrine. Lancet 1993; 341: 1541-2
4. Toivonen L, Viitasalo M, Siikamaki H, et al. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol 1994; 17: 403-4
5. FDA, HHS. International conference on harmonization: guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs - availability. Fed Regist 2005; 70: 61134-5
6. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15: 475-95
7. Malik M. Drug-induced QT interval prolongation: why is it of concern [online]? Available from URL: http://www.fda. gov/ohrms/dockets/ac/03/slides/ 4000S1-05-Malik-files/ frame.htm [Accessed 2009 May 12]
8. Batchvarov VN, Ghuran A, Smetana P, et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002; 282: H2356-63
9. Malik M, Hnatkova K, Novotny T, et al. Subject-specific profiles of QT/RR hysteresis. Am J Physiol Heart Circ Physiol 2008; 295: H2356-63
10. Smetana P, Batchvarov VN, Hnatkova K, et al. Ventricular gradient and nondipolar repolarization components increase at higher heart rate. Am J Physiol Heart Circ Physiol 2004; 286: H131-6
11. Malik M, Hnatkova K, Schmidt A, et al. Accurately measured and properly heart-rate corrected QTc intervals show little daytime variability. Heart Rhythm 2008; 5: 1424-31
12. Wylie Jr JV, Zimetbaum P, Josephson ME, et al. Cardiac memory induced by QRS widening due to propafenone toxicity. Pacing Clin Electrophysiol 2007; 30: 1161-4
13. Yue AM, Betts TR, Roberts PR, et al. Global dynamic coupling of activation and repolarization in the human ventricle. Circulation 2005; 112: 2592-601
14. Couderc JP,McNitt S, Hyrien O, et al. Improving the detection of subtle I(Kr)-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin. Drug Saf 2008; 31: 249-60
15. Graff C, Andersen MP, Xue JQ, et al. Identifying druginduced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology. Drug Saf 2009; 32 (7): 599-611
16. Couderc JP, Zareba W, Moss AJ, et al. Identification of sotalol-induced changes in repolarization with T wave area-based repolarization duration parameters. J Electrocardiol 2003; 36: 115-20
17. Sarapa N, Morganroth J, Couderc JP, et al. Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording methods. Ann Noninvasive Electrocardiol 2004; 9: 48-57